Literature DB >> 16185367

Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler.

David E Geller1.   

Abstract

Topically inhaled bronchodilators and corticosteroids are the mainstay of treatment for asthma and chronic obstructive pulmonary disease. These medications are delivered via jet or ultrasonic nebulizer, metered-dose inhaler (MDI), or dry powder inhaler (DPI). While the number of devices may be confusing to patients and clinicians, each device has distinct advantages and disadvantages. Most clinical evidence shows that any of these devices will work for most situations, including exacerbations and in the stable outpatient setting. There is a high rate of errors in device use with all these devices, especially the MDI. In choosing a drug/device combination for a patient, the clinician must take into account several factors, including the cognitive and physical ability of the patient, ease of use, convenience, costs, and patient preferences. Clinicians should also have a rudimentary understanding of aerosol principles in order to be able to teach appropriate use of aerosol devices to their patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16185367

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  28 in total

1.  Inhaler devices for chronic obstructive pulmonary disease: insights from patients and healthcare practitioners.

Authors:  Mathieu Molimard; Paul Colthorpe
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2014-09-29       Impact factor: 2.849

Review 2.  Non-invasive delivery strategies for biologics.

Authors:  Aaron C Anselmo; Yatin Gokarn; Samir Mitragotri
Journal:  Nat Rev Drug Discov       Date:  2018-11-30       Impact factor: 84.694

3.  Prevalence of Low Peak Inspiratory Flow Rate at Discharge in Patients Hospitalized for COPD Exacerbation.

Authors:  Gulshan Sharma; Donald A Mahler; Valerie M Mayorga; Kathleen L Deering; Oing Harshaw; Vaidyanathan Ganapathy
Journal:  Chronic Obstr Pulm Dis       Date:  2017-07-15

Review 4.  In vitro characterization of the I-neb Adaptive Aerosol Delivery (AAD) system.

Authors:  Lucy E A Hardaker; Ross H M Hatley
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-04       Impact factor: 2.849

5.  Formulation and evaluation of carrier-free dry powder inhaler containing sildenafil.

Authors:  Thi-Tram Nguyen; Eun-Jin Yi; Kyu-Mok Hwang; Cheol-Hee Cho; Chun-Woong Park; Ju-Young Kim; Yun-Seok Rhee; Eun-Seok Park
Journal:  Drug Deliv Transl Res       Date:  2019-02       Impact factor: 4.617

6.  Chapter 9 - Nanoliposomal dry powder formulations.

Authors:  Gaurang Patel; Mahavir Chougule; Mandip Singh; Ambikanandan Misra
Journal:  Methods Enzymol       Date:  2009       Impact factor: 1.600

7.  The Delivery of High-Dose Dry Powder Antibiotics by a Low-Cost Generic Inhaler.

Authors:  Thaigarajan Parumasivam; Sharon S Y Leung; Patricia Tang; Citterio Mauro; Warwick Britton; Hak-Kim Chan
Journal:  AAPS J       Date:  2016-09-27       Impact factor: 4.009

8.  Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study.

Authors:  Heino Stass; Johannes Nagelschmitz; Stefan Willmann; Heinz Delesen; Abhishek Gupta; Sybille Baumann
Journal:  Clin Drug Investig       Date:  2013-06       Impact factor: 2.859

9.  Inhaled corticosteroids for asthma: impact of practice level device switching on asthma control.

Authors:  Mike Thomas; David Price; Henry Chrystyn; Andrew Lloyd; Angela E Williams; Julie von Ziegenweidt
Journal:  BMC Pulm Med       Date:  2009-01-02       Impact factor: 3.317

10.  Aerosol delivery by an ultrasonic nebulizer during different mechanical ventilation settings in a lung model--a pilot study.

Authors:  Michael Winterhalter; Michael Bund; Nawid Khaladj; Christian Hagl; Andre Simon; Ludwig Hoy; Siegfried Piepenbrock; Niels Rahe-Meyer
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.